HIMS
NVO
Another day, another Hims pop
Hims & Hers is doing what hot stocks do best: turning regulatory breadcrumbs into a full-on feast. Shares climbed again Friday after signals from Health and Human Services Secretary Robert F. Kennedy Jr. and FDA discussions suggested the rules around certain compounded peptide therapies could get a rethink.
Why investors care
For Hims, this isn’t just some abstract policy nerd fight. Compounded peptides sit close to the heart of its weight-loss strategy, so even the possibility of lighter restrictions can make the growth story look juicier. If you’re wondering why the stock keeps bouncing, that’s the answer: the market thinks the company’s access to popular treatments could get a little less complicated.
But it’s not all one big victory lap
Hims has already been threading the needle between regulatory scrutiny and commercial opportunity. It struck an agreement with Novo Nordisk to offer FDA-approved Wegovy and Ozempic options while dialing back some compounded offerings, which is basically the corporate version of wearing both a belt and suspenders.
The bigger picture
This is one of those cases where policy chatter can move a stock almost as much as earnings. Hims is scheduled to report first-quarter 2026 results on May 11, and management already said full-year revenue should land between $2.7 billion and $2.9 billion with adjusted EBITDA of $300 million to $375 million. Big picture: if the peptide path stays open, the bull case for Hims gets a little easier to believe.